Elo Mutual Pension Insurance Co Makes New Investment in Illumina, Inc. $ILMN

Elo Mutual Pension Insurance Co purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 24,419 shares of the life sciences company’s stock, valued at approximately $2,319,000.

Several other institutional investors have also recently modified their holdings of ILMN. Generali Asset Management SPA SGR lifted its position in Illumina by 51.6% during the third quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock valued at $2,113,000 after purchasing an additional 7,574 shares during the period. Andra AP fonden raised its stake in shares of Illumina by 426.3% during the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after buying an additional 83,017 shares during the last quarter. Aaron Wealth Advisors LLC raised its stake in shares of Illumina by 342.6% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after buying an additional 8,109 shares during the last quarter. Douglas Lane & Associates LLC lifted its holdings in shares of Illumina by 6.6% in the 3rd quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock valued at $29,214,000 after buying an additional 18,914 shares during the period. Finally, Nordea Investment Management AB boosted its stake in shares of Illumina by 148.6% in the third quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock worth $3,024,000 after buying an additional 19,519 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

ILMN opened at $128.97 on Thursday. The company has a market cap of $19.72 billion, a price-to-earnings ratio of 23.66, a PEG ratio of 2.48 and a beta of 1.45. The firm’s fifty day simple moving average is $134.74 and its two-hundred day simple moving average is $118.89. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the firm earned $0.95 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Stifel Nicolaus lifted their price target on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Wall Street Zen raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Evercore set a $150.00 price target on shares of Illumina in a report on Friday, February 6th. Robert W. Baird set a $137.00 price target on shares of Illumina in a research report on Friday, February 6th. Finally, Piper Sandler decreased their price objective on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Illumina presently has an average rating of “Hold” and an average price target of $129.69.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 2.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.